PK-biomarker-safety modelling aids choice of recommended phase II dose and schedule for AZD6738 (ATR inhibitor)
dc.contributor.author | Berges, A | |
dc.contributor.author | Cheung, A | |
dc.contributor.author | Pierce, A | |
dc.contributor.author | Dean, E | |
dc.contributor.author | Felicetti, B | |
dc.contributor.author | Standifer, N | |
dc.contributor.author | Smith, S | |
dc.contributor.author | Yates, J | |
dc.contributor.author | Lau, A | |
dc.contributor.author | Stephens, C | |
dc.contributor.author | Krebs, Matthew G | |
dc.contributor.author | Harrington, K | |
dc.contributor.author | Hollingsworth, S | |
dc.date.accessioned | 2019-09-11T09:09:18Z | |
dc.date.available | 2019-09-11T09:09:18Z | |
dc.date.issued | 2018 | en |
dc.identifier.citation | Berges A, Cheung SYA, Pierce AJ, Dean E, Felicetti B, Standifer N, et al. PK-biomarker-safety modelling aids choice of recommended phase II dose and schedule for AZD6738 (ATR inhibitor). Cancer Res. 2018;78(13). | en |
dc.identifier.doi | 10.1158/1538-7445.AM2018-CT118 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622035 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1158/1538-7445.AM2018-CT118 | en |
dc.title | PK-biomarker-safety modelling aids choice of recommended phase II dose and schedule for AZD6738 (ATR inhibitor) | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge | en |
dc.identifier.journal | Cancer Research | en |
dc.description.note | en] |